Controversies in osteoporosis management: antiresorptive therapy for preventing bone loss: when to use one or two antiresorptive agents?
Study Goal
The researchers aimed to evaluate the effectiveness of combination therapies, including calcium supplementation, in preventing bone loss in postmenopausal women and older women with impaired calcium absorption.
Results Summary
The study found that combination therapies, such as calcium with bisphosphonates or calcitriol, increased bone density more effectively than monotherapy, particularly in older women with impaired calcium absorption and postmenopausal women on weaker antiresorptives.
Population
Early postmenopausal women and older women over 65 years of age with impaired calcium absorption.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
combination therapies | increase | bone density | - | more than monotherapy | increase | #1 |
combination of bisphosphonates and calcium supplementation | decrease | bone loss | women who initially receive a weaker antiresorptive such as the SERM raloxifene | - | is necessary to prevent | #2 |
combination of calcitriol with bisphosphonates | increase | bone density | older women over 65 years of age who often have impaired calcium absorption | more than monotherapy | has been shown to increase | #3 |
Women who have significant bone loss or a new fracture on monotherapy are considered for combination therapy. Combination therapies increase bone density more than monotherapy by targeting different parts of the osteoclast pathway.In early postmenopausal women who are symptomatic, the use of combination antiresorptives should include hormone therapy with a bisphosphonate or with bazodoxifene. In women who initially receive a weaker antiresorptive such as the SERM raloxifene, a combination with bisphosphonates and calcium supplementation is necessary to prevent bone loss. In older women over 65 years of age who often have impaired calcium absorption, the combination of calcitriol with bisphosphonates has been shown to increase bone density more than monotherapy.